Lyra Therapeutics, Inc. LYRA
We take great care to ensure that the data presented and summarized in this overview for Lyra Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LYRA
View all-
Perceptive Advisors LLC New York, NY12.8MShares$116 Million0.07% of portfolio
-
Black Rock Inc. New York, NY2.83MShares$25.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.77MShares$16.1 Million0.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA1.39MShares$12.7 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.06MShares$9.65 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.02MShares$9.27 Million0.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX533KShares$4.86 Million0.01% of portfolio
-
State Street Corp Boston, MA489KShares$4.46 Million0.0% of portfolio
-
Ubs Group Ag434KShares$3.96 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY370KShares$3.38 Million0.0% of portfolio
Latest Institutional Activity in LYRA
Top Purchases
Top Sells
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Insider Transactions at LYRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2025
|
Jason Cavalier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
684
-0.13%
|
$5,472
$8.91 P/Share
|
|
Jul 10
2025
|
Maria Palasis President & CEO |
SELL
Open market or private sale
|
Direct |
1,565
-0.14%
|
$12,520
$8.91 P/Share
|
|
Jan 08
2025
|
Jason Cavalier Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
420,000
+44.68%
|
-
|
|
Jan 08
2025
|
Maria Palasis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+42.11%
|
-
|
|
Oct 16
2024
|
Jason Cavalier Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Oct 16
2024
|
Maria Palasis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+50.0%
|
-
|
|
Mar 18
2024
|
Harlan Waksal Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
275,000
+33.87%
|
-
|
|
Nov 10
2023
|
Harlan Waksal Executive Chair |
BUY
Open market or private purchase
|
Direct |
25,000
+8.71%
|
$50,000
$2.96 P/Share
|
|
May 31
2023
|
Nbvm Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,805,416
+20.88%
|
$3,610,832
$2.43 P/Share
|
|
May 31
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
3,610,832
+23.94%
|
$7,221,664
$2.49 P/Share
|
|
May 31
2023
|
Edward T Anderson |
BUY
Open market or private purchase
|
Indirect |
1,805,416
+20.88%
|
$3,610,832
$2.43 P/Share
|
|
Jan 31
2023
|
Robert E. Richard SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 31
2023
|
Corinne Noyes Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,667
+50.0%
|
-
|
|
Jun 10
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
4,000
+26.1%
|
$20,000
$5.05 P/Share
|
|
May 16
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
328
+4.28%
|
$1,640
$5.0 P/Share
|
|
May 13
2022
|
C Ann Merrifield |
BUY
Open market or private purchase
|
Direct |
3,500
+33.33%
|
$14,000
$4.81 P/Share
|
|
Apr 12
2022
|
Edward T Anderson |
BUY
Open market or private purchase
|
Direct |
118,483
+50.0%
|
$473,932
$4.22 P/Share
|
|
Apr 12
2022
|
Edward T Anderson |
BUY
Open market or private purchase
|
Indirect |
2,369,667
+36.72%
|
$9,478,668
$4.22 P/Share
|
|
Apr 12
2022
|
Nbvm Gp, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,369,667
+36.72%
|
$9,478,668
$4.22 P/Share
|
|
Apr 12
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
5,924,170
+42.98%
|
$23,696,680
$4.22 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.62M shares |
|---|
| Open market or private sale | 2.25K shares |
|---|